Key facts
- This page summarizes David M. Stack's Form 4 filing for Pacira BioSciences, Inc. (PCRX).
- 7 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 08 Jun 2022, 19:51.
David M. Stack - 06 Jun 2022 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)
- Reporting relationship
- CEO and Chairman, Director
- Issuer ticker
- PCRX
- Reported as of
- 06 Jun 2022
- Net transaction value
- -$1,561,998
- SEC form
- 4
- Accepted by SEC
- 08 Jun 2022, 19:51:00 UTC
- Prior SEC filing
- 02 May 2022
- Next SEC filing
- 07 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kristen Williams, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
David M. Stack filed Form 4 for Pacira BioSciences, Inc. (PCRX) on 08 Jun 2022.
Change
- Previous filing in this sequence was filed on 02 May 2022.
- Current net transaction value: -$1,561,998.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PCRX
transaction
Common Stock
Sale
- Transaction value
- $734,340
- Shares
- -11,965
- Change %
- -7.1%
- Price
- $61.37
- Shares after
- 156,079
- Date
- 06 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
PCRX
transaction
Common Stock
Sale
- Transaction value
- $416,005
- Shares
- -7,039
- Change %
- -4.5%
- Price
- $59.10
- Shares after
- 149,040
- Date
- 08 Jun 2022
- Ownership
- Direct
- Footnotes
- F2, F3
PCRX
transaction
Common Stock
Sale
- Transaction value
- $302,012
- Shares
- -5,006
- Change %
- -3.4%
- Price
- $60.33
- Shares after
- 144,034
- Date
- 08 Jun 2022
- Ownership
- Direct
- Footnotes
- F2, F4
PCRX
transaction
Common Stock
Sale
- Transaction value
- $78,599
- Shares
- -1,282
- Change %
- -0.89%
- Price
- $61.31
- Shares after
- 142,752
- Date
- 08 Jun 2022
- Ownership
- Direct
- Footnotes
- F2, F5
PCRX
transaction
Common Stock
Sale
- Transaction value
- $31,042
- Shares
- -501
- Change %
- -0.35%
- Price
- $61.96
- Shares after
- 142,251
- Date
- 08 Jun 2022
- Ownership
- Direct
- Footnotes
- F2, F6
PCRX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +21,500
- Change %
- +15%
- Price
- $0.000000
- Shares after
- 163,751
- Date
- 08 Jun 2022
- Ownership
- Direct
- Footnotes
- F7
PCRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 97,273
- Date
- 06 Jun 2022
- Ownership
- By Three Colleens Investment, LLC
- Footnotes
- F8
PCRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 18,596
- Date
- 06 Jun 2022
- Ownership
- By Stack Schroon Mohawk FLP
- Footnotes
- F8
PCRX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 315
- Date
- 06 Jun 2022
- Ownership
- LCK Investment LLC
- Footnotes
- F8
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PCRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +160,900
- Change %
- Price
- $0.000000
- Shares after
- 160,900
- Date
- 08 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 160,900
- Exercise price
- $59.39
- Footnotes
- F9
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 9 footnotes
Footnote F1
Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units.
Footnote F2
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
Footnote F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.79 to $59.73, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 through 6.
Footnote F4
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.83 to $60.82, inclusive.
Footnote F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.840 to $61.825, inclusive.
Footnote F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.89 to $62.24, inclusive.
Footnote F7
Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2023, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
Footnote F8
Mr. Stack and his wife are the owners of each of Three Colleens Investment, LLC and LCK Investment LLC. Mr. Stack is the general partner of Stack Schroon Mohawk FLP.
Footnote F9
The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.